Info@ThinkPinkRocks.com

Esperion reports positive results from ETC-1002 Phase 2 clinical trial on type 2 diabetes

Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo.

Continue reading here:
Esperion reports positive results from ETC-1002 Phase 2 clinical trial on type 2 diabetes

Share

Leave a Reply

Solve : *
22 − 1 =